Skip to content

Evaluation of Safety and Efficacy of Eladi Quatha in Urolithiasis

PREPERATION AND EVALUATION OF ELADI QUATHA FOR KIDNEY DISORDERS FOR SPECIAL REFERENCE TO UROLITHIASIS

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031347
Enrollment
60
Registered
2021-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N200- Calculus of kidney

Interventions

Control Intervention1: Vasagudyachi Quatha : Used in urolithiasis as like Eladi Quatha Dose: 30ml Frequency: Twice a day Route of Administration: Oral Duration of the therapy: 1 Month

Sponsors

Parul Institute of Ayurveda
Lead Sponsor
CHARUSAT
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients should Clinically and pathologically diagnosed patient Size of the stone up to 10mm. Stone present in Upper Calyx, ureter, urinary bladder. Multiple urinary stone Subjects willing to sign informed consent. 6. Patients having mild and moderate hydronephrosis.

Exclusion criteria

Exclusion criteria: Patients with obstructive uropathy. Patients taking any other medicine for kidney stone. Patients suffering from any major systemic disease like diabetes mellitus, renal failure, renal tuberculosis etc. Benign prostatic hyperplasia. Size of stone more than >10mm. Patient having gross hydro nephrosis.

Design outcomes

Primary

MeasureTime frame
Scientific evidences will establish by this study within so industry and students can refer for the future reference in cases of urolithiasisTimepoint: 4 Weeks treatment duration will establish evidence by this study so industry and students can refer for the future reference

Secondary

MeasureTime frame
improvement in urolithiasisTimepoint: one month

Countries

India

Contacts

Public ContactDrHemant Toshikhane

Ramanbhai Patel College of Pharmacy (RPCP)

jalpasuthar.ph@charusat.ac.in9825907538

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026